NEW YORK (Reuters Health)—Interleukin (IL) 1 beta is a key player in the osteoarthritis (OA) inflammatory process and inhibiting it may help slow the disease process, according to an exploratory analysis of data from the CANTOS trial.1 CANTOS participants who were treated with the IL-1-beta inhibitor canakinumab had a significantly lower rate of total hip…
Search results for: hip OA
5 Takeaways from the 2018 Rheumatology Fellowship Match Data
If you’re a rheumatologist, you likely remember the moment of truth on your match day—the day of revelation, when the complex computer algorithm set up by the National Resident Matching Program (NRMP) accommodates the wishes of programs and applicants and then discloses into which program an applicant has been placed. Although it has always been…
Telemedicine & Fellowship Education After COVID-19: Q&A with Kanika Monga, MD
The COVID-19 pandemic is reshaping clinical rheumatology and the fellowship experience. Rheumatology education should include how to triage patients for remote visits, says second-year fellow Kanika Monga, MD…
Clinical Pearls: What We Know About Nonradiographic Axial Spondyloarthritis
ACR BEYOND LIVE—Much, if not all, of rheumatology relies on clinical interpretation of historical, laboratory and imaging information to formulate a coherent diagnosis and treatment plan—even when such information is incomplete or has multiple possible interpretations. One of the best examples of this situation pertains to nonradiographic axial spondyloarthritis (nr-axSpA), a condition that is just…
Fellowship Training Goes Virtual: COVID-19 Pandemic Creates Training Challenges
With telemedicine platforms and Zoom calls, technology is playing a large role in how rheumatology fellows are seeing patients and participating in lectures and conferences…
The COVID-19 Global Rheumatology Alliance: Its Genesis, Development & Goals
Editor’s note: We are sad to announce that we have learned of the passing of Dr. Philip C. Robinson. We will share more as it becomes available, but in the meantime, we wanted to repost this article he wrote for The Rheumatologist early in the pandemic. Dr. Robinson also took the photo of the full-arc rainbow below.
Collaborating at the Leadership Level: Q&A with Lisa Fitzgerald, MD, & George Tsokos, MD
Rheumatology leaders are adapting to telemedicine and other modified collaborations to adjust patient care and research during the COVID-19 pandemic…
FDA Considers Tanezumab Application for Chronic OA Pain
The FDA is considering an application for subcutaneous tanezumab, a monoclonal antibody, as a treatment for moderate to severe osteoarthritis…
Axial Spondyloarthritis & Exercise: Should axSpA Patients Exercise?
Two experts weigh in on whether & how axial spondyloarthritis patients should exercise…
Clinicians Discuss Current & Future Rheumatoid Arthritis Approaches
ATLANTA—When it comes to treating rheumatoid arthritis (RA) patients, most clinicians agree: One size does not fit all. Many treatment options exist, and seldom is there 100% consensus on what the first course of action or general approach should be. In the face of such variability, four clinicians took the stage at the 2019 ACR/ARP…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 330
- Next Page »